In stage IV, molecular profiling (gene testing for EGFR, ALK, ROS1 and BRAF) was performed in 94.3% of patients with adenocarcinoma, non-specific carcinoma, or nonsmoking squamous cell carcinoma. This evidence concerns the gene ALK and adenocarcinoma.